Added to YB: 2024-11-27
Pitch date: 2024-11-26
NVO [bullish]
Novo Nordisk A/S
-51.44%
current return
Author Info
Long-Term Pick shares in-depth stock analysis on high-quality stocks with growth potential. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 103.72
Price Target
124.92 (+149%)
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: Diabetes Care Leader Below Fair Price
NVO: Leader in diabetes/obesity care with 34% global market share. Q3 revenue +23% YoY to DKK 204.7B. Strong pipeline, 54% GLP-1 market share. Expanding into new therapeutic areas. Trades at attractive PEG ratio. Risks: competition, supply constraints, pricing pressure. 46% upside potential.
Read full article (11 min)